Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DiaMedica Therapeutics Inc.DMAC · Entity 5813 | Director | June 01, 2026 | June 03, 2026 |
| INVE Technologies, Inc.INVE · Entity 7037 | Director | July 30, 2026 | August 03, 2026 |
| Medtronic plcMDT · Entity 2888 | SVP & Chief Medical & Science | November 05, 2021 | November 09, 2021 |
| Rockley Photonics Holdings LtdRKLY · Entity 122956 | Director | August 08, 2022 | August 31, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DiaMedica Therapeutics Inc.
Report date June 01, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.84 · Expires 2036-06-01 | Direct | 40,412 |
Reported balance
After 2026-06-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-01 · Grant · Acquired 40,412 · Balance 40,412 F1: Scheduled to vest in four equal quarterly installments. |
Filing footnotes · ownership attribution and instrument terms
F1: Scheduled to vest in four equal quarterly installments.
INVE Technologies, Inc.
Report date July 30, 2026 · Filed August 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 65,712 |
Reported balance
After 2026-07-30 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-07-30 · Grant · Acquired 17,544 · Balance 65,712 F1: Restricted Stock Units granted pursuant to Issuer's 2011 Incentive Compensation Plan vesting 1/12th monthly beginning the vesting commencement date of June 1, 2026. Vested shares will be delivered to the reporting person on the earlier of (i) three years from the initial vesting start date of the award or (ii) the separation of service. F2: Includes an aggregate of 16,082 shares of common stock issuable pursuant to restricted stock units that have not vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted Stock Units granted pursuant to Issuer's 2011 Incentive Compensation Plan vesting 1/12th monthly beginning the vesting commencement date of June 1, 2026. Vested shares will be delivered to the reporting person on the earlier of (i) three years from the initial vesting start date of the award or (ii) the separation of service.
F2: Includes an aggregate of 16,082 shares of common stock issuable pursuant to restricted stock units that have not vested.
Medtronic plc
Report date November 05, 2021 · Filed November 09, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 74,945 |
Reported balance
After 2021-11-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-11-05 · Tax withholding · Disposed 209 · Balance 74,945 F1: This balance increased by 239 shares due to exempt transactions such as dividend reinvestment. F2: The reported transaction involved the withholding of 209 shares of stock issuable upon the early vesting of an equal number of restricted stock units to pay taxes associated with the reporting person becoming retirement eligible. |
Filing footnotes · ownership attribution and instrument terms
F1: This balance increased by 239 shares due to exempt transactions such as dividend reinvestment.
F2: The reported transaction involved the withholding of 209 shares of stock issuable upon the early vesting of an equal number of restricted stock units to pay taxes associated with the reporting person becoming retirement eligible.
Rockley Photonics Holdings Ltd
Report date August 08, 2022 · Filed August 31, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 60,837 |
Reported balance
After 2022-08-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-08-08 · Grant · Acquired 60,837 · Balance 60,837 F1: Subject to continued service as a director, the RSU will vest on the earlier of the one-year anniversary of the date of grant or the 2023 annual meeting of shareholders, subject to acceleration upon a change in control. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to continued service as a director, the RSU will vest on the earlier of the one-year anniversary of the date of grant or the 2023 annual meeting of shareholders, subject to acceleration upon a change in control.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ZimVie Inc.
Report date October 20, 2025 · Filed October 20, 2025
Section 16 reporting ended · disclosed 2025-10-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Deferred Share UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-10-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-10-20 · Disposition to issuer · Disposed 13,072.965 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated July 20, 2025, by and among the Issuer, Zamboni Parent Inc., a Delaware corporation ("Parent"), and Zamboni MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on October 20, 2025 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. At the Effective Time, each share of the Issuer's common stock, par value $0.01 per share ("Common Stock"), reported on this Form 4 was converted into the right to receive $19.00 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled. F2: At the Effective Time, each deferred share unit (whether settled in cash or in shares of Common Stock, including any such deferred stock unit resulting from the reinvestment of dividend equivalents) (each, a "Deferred Share Unit") outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested) and was canceled and converted into the right to receive cash, without interest and subject to applicable tax withholding and deductions, in an amount equal to the product, rounded to the nearest cent, of (i) the number of shares of Common Stock subject to such Deferred Share Unit immediately prior to the Effective Time and (ii) the Merger Consideration. F4: As required by the terms of the Merger Agreement, the Issuer accelerated the vesting, as of immediately prior to the Effective Time, contingent upon the closing of the transactions contemplated by the Merger Agreement, of all of the outstanding and unvested equity awards held by Dr. Kuntz. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-10-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-10-20 · Disposition to issuer · Disposed 57,728 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated July 20, 2025, by and among the Issuer, Zamboni Parent Inc., a Delaware corporation ("Parent"), and Zamboni MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on October 20, 2025 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. At the Effective Time, each share of the Issuer's common stock, par value $0.01 per share ("Common Stock"), reported on this Form 4 was converted into the right to receive $19.00 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled. F3: At the Effective Time, each restricted stock unit with respect to Common Stock (each, a "Restricted Stock Unit") outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested) and was canceled and converted into the right to receive cash, without interest and subject to applicable tax withholding and deductions, in an amount equal to the product, rounded to the nearest cent, of (i) the number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time and (ii) the Merger Consideration. Each Restricted Stock Unit represented a contingent right to receive one share of Common Stock. F4: As required by the terms of the Merger Agreement, the Issuer accelerated the vesting, as of immediately prior to the Effective Time, contingent upon the closing of the transactions contemplated by the Merger Agreement, of all of the outstanding and unvested equity awards held by Dr. Kuntz. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated July 20, 2025, by and among the Issuer, Zamboni Parent Inc., a Delaware corporation ("Parent"), and Zamboni MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on October 20, 2025 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. At the Effective Time, each share of the Issuer's common stock, par value $0.01 per share ("Common Stock"), reported on this Form 4 was converted into the right to receive $19.00 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.
F2: At the Effective Time, each deferred share unit (whether settled in cash or in shares of Common Stock, including any such deferred stock unit resulting from the reinvestment of dividend equivalents) (each, a "Deferred Share Unit") outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested) and was canceled and converted into the right to receive cash, without interest and subject to applicable tax withholding and deductions, in an amount equal to the product, rounded to the nearest cent, of (i) the number of shares of Common Stock subject to such Deferred Share Unit immediately prior to the Effective Time and (ii) the Merger Consideration.
F3: At the Effective Time, each restricted stock unit with respect to Common Stock (each, a "Restricted Stock Unit") outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested) and was canceled and converted into the right to receive cash, without interest and subject to applicable tax withholding and deductions, in an amount equal to the product, rounded to the nearest cent, of (i) the number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time and (ii) the Merger Consideration. Each Restricted Stock Unit represented a contingent right to receive one share of Common Stock.
F4: As required by the terms of the Merger Agreement, the Issuer accelerated the vesting, as of immediately prior to the Effective Time, contingent upon the closing of the transactions contemplated by the Merger Agreement, of all of the outstanding and unvested equity awards held by Dr. Kuntz.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 30, 2026 Filed Aug 3, 2026 22:47 UTC | INVE Technologies, Inc. INVE · Entity 7037 | GrantCommon Stock | 17,544 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-331013 · ownership.xml · nonDerivative · entry 1 Kuntz Richard · CIK 0001341125 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,712 F1 · shares: Restricted Stock Units granted pursuant to Issuer's 2011 Incentive Compensation Plan vesting 1/12th monthly beginning the vesting commencement date of June 1, 2026. Vested shares will be delivered to the reporting person on the earlier of (i) three years from the initial vesting start date of the award or (ii) the separation of service. F2 · balance_after: Includes an aggregate of 16,082 shares of common stock issuable pursuant to restricted stock units that have not vested. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 21:27 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock Option (right to buy) · Derivative | 40,412 | $0.00 Strike: $5.84 | $0.00 |
DisclosureSEC source: 0001341125-26-000002 · form4-06032026_090653.xml · derivative · entry 1 Kuntz Richard · CIK 0001341125 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,412 Underlying: Voting Common Shares · 40,412 shares Expires 2036-06-01 F1 · derivative.exercise_date: Scheduled to vest in four equal quarterly installments. Read SEC document |
| October 20, 2025 Filed Oct 20, 2025 21:00 UTC | ZimVie Inc. ZIMV · Entity 74112 | Disposition to issuerRestricted Stock Units · Derivative | 57,728 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-25-243727 · ownership.xml · derivative · entry 2 Kuntz Richard · CIK 0001341125 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 57,728 shares Expires not disclosed F1 · derivative.exercise_price: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated July 20, 2025, by and among the Issuer, Zamboni Parent Inc., a Delaware corporation ("Parent"), and Zamboni MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on October 20, 2025 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. At the Effective Time, each share of the Issuer's common stock, par value $0.01 per share ("Common Stock"), reported on this Form 4 was converted into the right to receive $19.00 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled. F3 · derivative.exercise_price: At the Effective Time, each restricted stock unit with respect to Common Stock (each, a "Restricted Stock Unit") outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested) and was canceled and converted into the right to receive cash, without interest and subject to applicable tax withholding and deductions, in an amount equal to the product, rounded to the nearest cent, of (i) the number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time and (ii) the Merger Consideration. Each Restricted Stock Unit represented a contingent right to receive one share of Common Stock. F3 · price: At the Effective Time, each restricted stock unit with respect to Common Stock (each, a "Restricted Stock Unit") outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested) and was canceled and converted into the right to receive cash, without interest and subject to applicable tax withholding and deductions, in an amount equal to the product, rounded to the nearest cent, of (i) the number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time and (ii) the Merger Consideration. Each Restricted Stock Unit represented a contingent right to receive one share of Common Stock. F3 · derivative.exercise_date: At the Effective Time, each restricted stock unit with respect to Common Stock (each, a "Restricted Stock Unit") outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested) and was canceled and converted into the right to receive cash, without interest and subject to applicable tax withholding and deductions, in an amount equal to the product, rounded to the nearest cent, of (i) the number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time and (ii) the Merger Consideration. Each Restricted Stock Unit represented a contingent right to receive one share of Common Stock. F4 · derivative.exercise_date: As required by the terms of the Merger Agreement, the Issuer accelerated the vesting, as of immediately prior to the Effective Time, contingent upon the closing of the transactions contemplated by the Merger Agreement, of all of the outstanding and unvested equity awards held by Dr. Kuntz. F3 · derivative.expiration_date: At the Effective Time, each restricted stock unit with respect to Common Stock (each, a "Restricted Stock Unit") outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested) and was canceled and converted into the right to receive cash, without interest and subject to applicable tax withholding and deductions, in an amount equal to the product, rounded to the nearest cent, of (i) the number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time and (ii) the Merger Consideration. Each Restricted Stock Unit represented a contingent right to receive one share of Common Stock. F4 · derivative.expiration_date: As required by the terms of the Merger Agreement, the Issuer accelerated the vesting, as of immediately prior to the Effective Time, contingent upon the closing of the transactions contemplated by the Merger Agreement, of all of the outstanding and unvested equity awards held by Dr. Kuntz. Read SEC document |
| October 20, 2025 Filed Oct 20, 2025 21:00 UTC | ZimVie Inc. ZIMV · Entity 74112 | Disposition to issuerDeferred Share Units · Derivative | 13,072.965 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-25-243727 · ownership.xml · derivative · entry 1 Kuntz Richard · CIK 0001341125 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,072.965 shares Expires not disclosed F1 · derivative.exercise_price: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated July 20, 2025, by and among the Issuer, Zamboni Parent Inc., a Delaware corporation ("Parent"), and Zamboni MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on October 20, 2025 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. At the Effective Time, each share of the Issuer's common stock, par value $0.01 per share ("Common Stock"), reported on this Form 4 was converted into the right to receive $19.00 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled. F2 · derivative.exercise_price: At the Effective Time, each deferred share unit (whether settled in cash or in shares of Common Stock, including any such deferred stock unit resulting from the reinvestment of dividend equivalents) (each, a "Deferred Share Unit") outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested) and was canceled and converted into the right to receive cash, without interest and subject to applicable tax withholding and deductions, in an amount equal to the product, rounded to the nearest cent, of (i) the number of shares of Common Stock subject to such Deferred Share Unit immediately prior to the Effective Time and (ii) the Merger Consideration. F2 · price: At the Effective Time, each deferred share unit (whether settled in cash or in shares of Common Stock, including any such deferred stock unit resulting from the reinvestment of dividend equivalents) (each, a "Deferred Share Unit") outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested) and was canceled and converted into the right to receive cash, without interest and subject to applicable tax withholding and deductions, in an amount equal to the product, rounded to the nearest cent, of (i) the number of shares of Common Stock subject to such Deferred Share Unit immediately prior to the Effective Time and (ii) the Merger Consideration. F2 · derivative.exercise_date: At the Effective Time, each deferred share unit (whether settled in cash or in shares of Common Stock, including any such deferred stock unit resulting from the reinvestment of dividend equivalents) (each, a "Deferred Share Unit") outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested) and was canceled and converted into the right to receive cash, without interest and subject to applicable tax withholding and deductions, in an amount equal to the product, rounded to the nearest cent, of (i) the number of shares of Common Stock subject to such Deferred Share Unit immediately prior to the Effective Time and (ii) the Merger Consideration. F4 · derivative.exercise_date: As required by the terms of the Merger Agreement, the Issuer accelerated the vesting, as of immediately prior to the Effective Time, contingent upon the closing of the transactions contemplated by the Merger Agreement, of all of the outstanding and unvested equity awards held by Dr. Kuntz. F2 · derivative.expiration_date: At the Effective Time, each deferred share unit (whether settled in cash or in shares of Common Stock, including any such deferred stock unit resulting from the reinvestment of dividend equivalents) (each, a "Deferred Share Unit") outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested) and was canceled and converted into the right to receive cash, without interest and subject to applicable tax withholding and deductions, in an amount equal to the product, rounded to the nearest cent, of (i) the number of shares of Common Stock subject to such Deferred Share Unit immediately prior to the Effective Time and (ii) the Merger Consideration. F4 · derivative.expiration_date: As required by the terms of the Merger Agreement, the Issuer accelerated the vesting, as of immediately prior to the Effective Time, contingent upon the closing of the transactions contemplated by the Merger Agreement, of all of the outstanding and unvested equity awards held by Dr. Kuntz. Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 20:09 UTC | ZimVie Inc. ZIMV · Entity 74112 | GrantDeferred Share Units · Derivative | 662.309 | $0.00 Strike: $18.93 | $0.00 |
DisclosureSEC source: 0001341125-25-000005 · form4-10022025_081012.xml · derivative · entry 1 Kuntz Richard · CIK 0001341125 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,072.965 Underlying: Common Stock · 662.309 shares Expires not disclosed F1 · security: The deferred share units were accrued under the ZimVie Inc. (the "Company") Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Securities is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: Units are to be settled in cash after cessation of the reporting person's service as a Director. Read SEC document |
| July 29, 2025 Filed Jul 31, 2025 20:52 UTC | INVE Technologies, Inc. INVE · Entity 7037 | GrantCommon Stock | 21,148 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-100967 · ownership.xml · nonDerivative · entry 1 Kuntz Richard · CIK 0001341125 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,168 F1 · shares: Restricted Stock Units granted pursuant to Issuer's 2011 Incentive Compensation Plan vesting 1/12th monthly beginning the vesting commencement date of June 1, 2025. Vested shares will be delivered to the reporting person on the earlier of (i) three years from the initial vesting start date of the award or (ii) the separation of service. F2 · balance_after: Includes an aggregate of 19,386 shares of common stock issuable pursuant to restricted stock units that have not vested. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 20:36 UTC | ZimVie Inc. ZIMV · Entity 74112 | GrantDeferred Share Units · Derivative | 1,340.909 | $0.00 Strike: $9.35 | $0.00 |
DisclosureSEC source: 0001062993-25-012468 · form4.xml · derivative · entry 1 Kuntz Richard · CIK 0001341125 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,410.656 Underlying: Common Stock · 1,340.909 shares Expires not disclosed F1 · security: The deferred share units were accrued under the ZimVie Inc. ("Company") Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: Units are to be settled in cash after cessation of the reporting person's service as a Director. Read SEC document |
| June 01, 2025 Filed Jun 3, 2025 20:16 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock Option (right to buy) · Derivative | 32,162 | $0.00 Strike: $4.11 | $0.00 |
DisclosureSEC source: 0001437749-25-019291 · rdgdoc.xml · derivative · entry 2 Kuntz Richard · CIK 0001341125 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,162 Underlying: Common Shares · 32,162 shares Expires 2035-05-31 F2 · derivative.exercise_date: Vests in four nearly equal quarterly installments over one year. Read SEC document |
| May 07, 2025 Filed May 9, 2025 21:34 UTC | ZimVie Inc. ZIMV · Entity 74112 | GrantRestricted Stock Units · Derivative | 21,119 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-009038 · form4.xml · derivative · entry 2 Kuntz Richard · CIK 0001341125 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,728 Underlying: Common Stock · 21,119 shares Expires not disclosed F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F4 · derivative.exercise_date: The Restricted Stock Units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination of service as a Director or (2) the date that is three years after the grant date. F4 · derivative.expiration_date: The Restricted Stock Units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination of service as a Director or (2) the date that is three years after the grant date. Read SEC document |
| May 07, 2025 Filed May 9, 2025 21:34 UTC | ZimVie Inc. ZIMV · Entity 74112 | GrantDeferred Share Units · Derivative | 500 | $0.00 Strike: $8.76 | $0.00 |
DisclosureSEC source: 0001062993-25-009038 · form4.xml · derivative · entry 1 Kuntz Richard · CIK 0001341125 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,069.747 Underlying: Common Stock · 500 shares Expires not disclosed F1 · security: The deferred share units were accrued under the ZimVie Inc. ("Company") Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: The units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: The units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:22 UTC | ZimVie Inc. ZIMV · Entity 74112 | GrantDeferred Share Units · Derivative | 1,163.033 | $0.00 Strike: $10.78 | $0.00 |
DisclosureSEC source: 0001062993-25-006867 · form4.xml · derivative · entry 1 Kuntz Richard · CIK 0001341125 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,569.747 Underlying: Common Stock · 1,163.033 shares Expires not disclosed F1 · security: The deferred share units were accrued under the ZimVie Inc. ("Company") Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: Units are to be settled in cash after cessation of the reporting person's service as a Director. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 21:28 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantVoting Common Shares, no par value per share | 9,925 | $5.34 | $52,999.50 |
DisclosureSEC source: 0001235802-25-000003 · primary_doc.xml · nonDerivative · entry 1 Kuntz Richard · CIK 0001341125 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,210 F1 · shares: These shares are issuable upon vesting and settlement of a restricted stock unit award granted under the DiaMedica Therapeutics Inc. Amended and Restated 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $53,000. The restricted stock unit award will vest in four nearly equal installments on each of March 31, 2025, June 30, 2025, September 30, 2025 and December 31, 2025. F2 · balance_after: Includes 9,925 shares issuable on vesting of a restricted stock unit award granted under the DiaMedica Therapeutics Inc. Amended and Restated 2019 Omnibus Incentive Plan. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 15:01 UTC | ZimVie Inc. ZIMV · Entity 74112 | GrantDeferred Share Units · Derivative | 894.897 | $0.00 Strike: $14.01 | $0.00 |
DisclosureSEC source: 0001062993-25-000044 · form4.xml · derivative · entry 1 Kuntz Richard · CIK 0001341125 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,406.714 Underlying: Common Stock · 894.897 shares Expires not disclosed F1 · security: The deferred share units were accrued under the ZimVie Inc. ("Company") Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: Units are to be settled in cash after cessation of the reporting person's service as a Director. Read SEC document |
| September 30, 2024 Filed Oct 2, 2024 20:09 UTC | ZimVie Inc. ZIMV · Entity 74112 | GrantDeferred Share Units · Derivative | 795.022 | $0.00 Strike: $15.77 | $0.00 |
DisclosureSEC source: 0001062993-24-017242 · form4.xml · derivative · entry 1 Kuntz Richard · CIK 0001341125 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,511.817 Underlying: Common Stock · 795.022 shares Expires not disclosed F1 · security: The deferred share units were accrued under the ZimVie Inc. ("Company") Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: Units are to be settled in cash after cessation of the reporting person's service as a Director. Read SEC document |
| July 29, 2024 Filed Oct 23, 2024 23:41 UTC | INVE Technologies, Inc. INVE · Entity 7037 | GrantCommon Stock | 14,773 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-116778 · ownership.xml · nonDerivative · entry 1 Kuntz Richard · CIK 0001341125 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,020 F1 · shares: Restricted Stock Units granted pursuant to Issuer's 2011 Incentive Compensation Plan vesting 1/12th monthly beginning the vesting commencement date of June 1, 2024. Vested shares will be delivered to the reporting person on the earlier of (i) three years from the initial vesting start date of the award or (ii) the separation of service. Read SEC document |
| June 30, 2024 Filed Jul 2, 2024 20:38 UTC | ZimVie Inc. ZIMV · Entity 74112 | GrantDeferred Share Units · Derivative | 696.915 | $0.00 Strike: $17.99 | $0.00 |
DisclosureSEC source: 0001062993-24-013315 · form4.xml · derivative · entry 1 Kuntz Richard · CIK 0001341125 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,716.795 Underlying: Common Stock · 696.915 shares Expires not disclosed F1 · security: The deferred share units were accrued under the ZimVie Inc. ("Company") Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: Units are to be settled in cash after cessation of the reporting person's service as a Director. Read SEC document |
| June 01, 2024 Filed Jun 3, 2024 20:09 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock Option (right to buy) · Derivative | 28,472 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001235802-24-000045 · primary_doc.xml · derivative · entry 2 Kuntz Richard · CIK 0001341125 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,472 Underlying: Common Shares · 28,472 shares Expires 2034-05-31 F2 · derivative.exercise_date: Vests in four nearly equal quarterly installments over one year. Read SEC document |
| May 15, 2024 Filed May 17, 2024 20:14 UTC | ZimVie Inc. ZIMV · Entity 74112 | GrantRestricted Stock Units · Derivative | 11,012 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-010620 · form4.xml · derivative · entry 2 Kuntz Richard · CIK 0001341125 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,609 Underlying: Common Stock · 11,012 shares Expires not disclosed F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F4 · derivative.exercise_date: The Restricted Stock Units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination of service as a Director or (2) the date that is three years after the grant date. F4 · derivative.expiration_date: The Restricted Stock Units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination of service as a Director or (2) the date that is three years after the grant date. Read SEC document |
| May 15, 2024 Filed May 17, 2024 20:14 UTC | ZimVie Inc. ZIMV · Entity 74112 | GrantDeferred Share Units · Derivative | 500 | $0.00 Strike: $16.80 | $0.00 |
DisclosureSEC source: 0001062993-24-010620 · form4.xml · derivative · entry 1 Kuntz Richard · CIK 0001341125 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,019.88 Underlying: Common Stock · 500 shares Expires not disclosed F1 · security: The deferred share units were accrued under the ZimVie Inc. ("Company") Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: The units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: The units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. Read SEC document |
| March 31, 2024 Filed Apr 2, 2024 20:05 UTC | ZimVie Inc. ZIMV · Entity 74112 | GrantDeferred Share Units · Derivative | 764.016 | $0.00 Strike: $16.41 | $0.00 |
DisclosureSEC source: 0001062993-24-007700 · form4.xml · derivative · entry 1 Kuntz Richard · CIK 0001341125 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,519.88 Underlying: Common Stock · 764.016 shares Expires not disclosed F1 · security: The deferred share units were accrued under the ZimVie Inc. ("Company") Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: Units are to be settled in cash after cessation of the reporting person's service as a Director. Read SEC document |
| January 02, 2024 Filed Jan 2, 2024 22:00 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantVoting Common Shares, no par value per share | 14,285 | $2.80 | $39,998.00 |
DisclosureSEC source: 0001235802-24-000004 · primary_doc.xml · nonDerivative · entry 1 Kuntz Richard · CIK 0001341125 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,285 F1 · shares: These shares are issuable upon vesting of a restricted stock unit award granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $40,000. The restricted stock unit award will vest in four nearly equal installments on each of March 31, 2024, June 30, 2024, September 30, 2024 and December 31, 2024. F1 · balance_after: These shares are issuable upon vesting of a restricted stock unit award granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $40,000. The restricted stock unit award will vest in four nearly equal installments on each of March 31, 2024, June 30, 2024, September 30, 2024 and December 31, 2024. Read SEC document |
| August 01, 2023 Filed Aug 2, 2023 16:24 UTC | INVE Technologies, Inc. INVE · Entity 7037 | GrantCommon Stock | 8,904 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-036915 · ownership.xml · nonDerivative · entry 1 Kuntz Richard · CIK 0001341125 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,247 F1 · shares: Restricted Stock Units granted pursuant to Issuer's 2011 Incentive Compensation Plan vesting 1/12th monthly beginning the vesting commencement date of June 1, 2023. Vested shares will be delivered to the reporting person on the earlier of (i) three years from the initial vesting start date of the award or (ii) the separation of service. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 21:21 UTC | ZimVie Inc. ZIMV · Entity 74112 | GrantDeferred Share Units · Derivative | 762.86 | $0.00 Strike: $11.47 | $0.00 |
DisclosureSEC source: 0001062993-23-014502 · form4.xml · derivative · entry 1 Kuntz Richard · CIK 0001341125 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,755.864 Underlying: Common Stock · 762.86 shares Expires not disclosed F1 · security: The deferred share units were accrued under the ZimVie Inc. ("Company") Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: Units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. Read SEC document |
| May 30, 2023 Filed May 30, 2023 22:18 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock option (right to buy) · Derivative | 32,320 | $0.00 Strike: $2.81 | $0.00 |
DisclosureSEC source: 0001790300-23-000003 · primary_doc.xml · derivative · entry 2 Kuntz Richard · CIK 0001341125 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,320 Underlying: Common Shares · 32,320 shares Expires 2033-05-29 F1 · derivative.exercise_date: Vests in 12 nearly equal quarterly installments over three years. Read SEC document |
| May 12, 2023 Filed May 16, 2023 20:43 UTC | ZimVie Inc. ZIMV · Entity 74112 | GrantRestricted Stock Units · Derivative | 17,704 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-011240 · form4.xml · derivative · entry 2 Kuntz Richard · CIK 0001341125 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,597 Underlying: Common Stock · 17,704 shares Expires not disclosed F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F4 · derivative.exercise_date: The Restricted Stock Units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination of service as a Director or (2) the date that is three years after the grant date. F4 · derivative.expiration_date: The Restricted Stock Units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination of service as a Director or (2) the date that is three years after the grant date. Read SEC document |
| May 12, 2023 Filed May 16, 2023 20:43 UTC | ZimVie Inc. ZIMV · Entity 74112 | GrantDeferred Share Units · Derivative | 500 | $0.00 Strike: $10.45 | $0.00 |
DisclosureSEC source: 0001062993-23-011240 · form4.xml · derivative · entry 1 Kuntz Richard · CIK 0001341125 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,993.004 Underlying: Common Stock · 500 shares Expires not disclosed F1 · security: The deferred share units were accrued under the ZimVie Inc. ("Company") Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: The units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: The units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:02 UTC | ZimVie Inc. ZIMV · Entity 74112 | GrantDeferred Share Units · Derivative | 1,241.135 | $0.00 Strike: $7.05 | $0.00 |
DisclosureSEC source: 0001062993-23-008463 · form4.xml · derivative · entry 1 Kuntz Richard · CIK 0001341125 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,493.004 Underlying: Common Stock · 1,241.135 shares Expires not disclosed F1 · security: The deferred share units were accrued under the ZimVie Inc. ("Company") Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: Units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. Read SEC document |
| December 31, 2022 Filed Jan 4, 2023 21:03 UTC | ZimVie Inc. ZIMV · Entity 74112 | GrantDeferred Share Units · Derivative | 957.33 | $0.00 Strike: $9.14 | $0.00 |
DisclosureSEC source: 0001062993-23-000240 · form4.xml · derivative · entry 1 Kuntz Richard · CIK 0001341125 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,251.869 Underlying: Common Stock · 957.33 shares Expires not disclosed F1 · security: The deferred share units were accrued under the ZimVie Inc. ("Company") Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: Units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. Read SEC document |
| October 31, 2022 Filed Nov 2, 2022 20:59 UTC | INVE Technologies, Inc. INVE · Entity 7037 | GrantCommon Stock | 3,343 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-034775 · doc4.xml · nonDerivative · entry 1 Kuntz Richard · CIK 0001341125 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,343 F1 · shares: Restricted Stock Units granted pursuant to Issuer's 2011 Incentive Compensation Plan vest on a monthly basis beginning on the vesting commencement date of October 18, 2022 through May 31, 2023. Vested shares will be delivered to the reporting person on the earlier of (i) three years from the initial vesting start date of the award or (ii) the separation of service. Read SEC document |
| September 30, 2022 Filed Oct 4, 2022 20:05 UTC | ZimVie Inc. ZIMV · Entity 74112 | GrantDeferred Share Units · Derivative | 870.647 | $0.00 Strike: $10.05 | $0.00 |
DisclosureSEC source: 0001062993-22-020310 · form4.xml · derivative · entry 1 Kuntz Richard · CIK 0001341125 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,294.539 Underlying: Common Stock · 870.647 shares Expires not disclosed F1 · security: The deferred share units were accrued under the ZimVie Inc. ("Company") Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: Units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 20:19 UTC | Rockley Photonics Holdings Ltd RKLY · Entity 122956 | GrantRestricted Stock Unit · Derivative | 107,317 | $0.00 | $0.00 |
DisclosureSEC source: 0001852117-22-000266 · wf-form4_166017713817248.xml · derivative · entry 1 Kuntz Richard · CIK 0001341125 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,317 Underlying: Ordinary Share · 107,317 shares Expires not disclosed F1 · derivative.exercise_price: Subject to continued service as a director, the RSU vests as to 1/3 of the shares upon the earlier of the first anniversary of the date of grant or the Company's 2023 annual meeting of shareholders, and in each of the next two calendar years following the initial vesting date, 1/3 of the shares will vest on the earlier of the one year anniversary of the prior annual meeting of shareholders or the then current year's annual meeting of shareholders. F1 · derivative.exercise_date: Subject to continued service as a director, the RSU vests as to 1/3 of the shares upon the earlier of the first anniversary of the date of grant or the Company's 2023 annual meeting of shareholders, and in each of the next two calendar years following the initial vesting date, 1/3 of the shares will vest on the earlier of the one year anniversary of the prior annual meeting of shareholders or the then current year's annual meeting of shareholders. F1 · derivative.expiration_date: Subject to continued service as a director, the RSU vests as to 1/3 of the shares upon the earlier of the first anniversary of the date of grant or the Company's 2023 annual meeting of shareholders, and in each of the next two calendar years following the initial vesting date, 1/3 of the shares will vest on the earlier of the one year anniversary of the prior annual meeting of shareholders or the then current year's annual meeting of shareholders. Read SEC document |
| August 08, 2022 Filed Aug 31, 2022 18:59 UTC | Rockley Photonics Holdings Ltd RKLY · Entity 122956 | GrantRestricted Stock Unit · Derivative | 60,837 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001852117-22-000316 · wf-form4_166198678274486.xml · derivative · entry 1 Kuntz Richard · CIK 0001341125 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,837 Underlying: Ordinary Share · 60,837 shares Expires not disclosed F1 · derivative.exercise_date: Subject to continued service as a director, the RSU will vest on the earlier of the one-year anniversary of the date of grant or the 2023 annual meeting of shareholders, subject to acceleration upon a change in control. F1 · derivative.expiration_date: Subject to continued service as a director, the RSU will vest on the earlier of the one-year anniversary of the date of grant or the 2023 annual meeting of shareholders, subject to acceleration upon a change in control. Read SEC document |
| June 30, 2022 Filed Jul 5, 2022 20:04 UTC | ZimVie Inc. ZIMV · Entity 74112 | GrantDeferred Share Units · Derivative | 541.796 | $0.00 Strike: $16.15 | $0.00 |
DisclosureSEC source: 0001062993-22-015846 · form4.xml · derivative · entry 1 Kuntz Richard · CIK 0001341125 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,423.892 Underlying: Common Stock · 541.796 shares Expires not disclosed F1 · security: The deferred share units were accrued under the ZimVie Inc. ("Company") Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: Units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. Read SEC document |
| April 01, 2022 Filed Apr 4, 2022 21:17 UTC | ZimVie Inc. ZIMV · Entity 74112 | GrantRestricted Stock Units · Derivative | 7,893 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-009504 · form4.xml · derivative · entry 3 Kuntz Richard · CIK 0001341125 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,893 Underlying: Common Stock · 7,893 shares Expires not disclosed F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F4 · derivative.exercise_date: The Restricted Stock Units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination of service as a Director or (2) the date that is three years after the grant date. F4 · derivative.expiration_date: The Restricted Stock Units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination of service as a Director or (2) the date that is three years after the grant date. Read SEC document |
| April 01, 2022 Filed Apr 4, 2022 21:17 UTC | ZimVie Inc. ZIMV · Entity 74112 | GrantDeferred Share Units · Derivative | 500 | $0.00 Strike: $23.44 | $0.00 |
DisclosureSEC source: 0001062993-22-009504 · form4.xml · derivative · entry 2 Kuntz Richard · CIK 0001341125 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 882.096 Underlying: Common Stock · 500 shares Expires not disclosed F1 · security: The deferred share units were accrued under the ZimVie Inc. ("Company") Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: Units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 21:17 UTC | ZimVie Inc. ZIMV · Entity 74112 | GrantDeferred Share Units · Derivative | 382.096 | $0.00 Strike: $22.90 | $0.00 |
DisclosureSEC source: 0001062993-22-009504 · form4.xml · derivative · entry 1 Kuntz Richard · CIK 0001341125 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 382.096 Underlying: Common Stock · 382.096 shares Expires not disclosed F1 · security: The deferred share units were accrued under the ZimVie Inc. ("Company") Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: Units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. Read SEC document |
| November 05, 2021 Filed Nov 9, 2021 22:58 UTC | Medtronic plc MDT · Entity 2888 | Tax withholdingOrdinary Shares | 209 | $122.98 | $25,702.82 |
DisclosureSEC source: 0001127602-21-028739 · form4.xml · nonDerivative · entry 1 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,945 F1 · balance_after: This balance increased by 239 shares due to exempt transactions such as dividend reinvestment. F2 · balance_after: The reported transaction involved the withholding of 209 shares of stock issuable upon the early vesting of an equal number of restricted stock units to pay taxes associated with the reporting person becoming retirement eligible. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 22:16 UTC | Medtronic plc MDT · Entity 2888 | GrantPerformance Share Units · Derivative | 12,571 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-023100 · form4.xml · derivative · entry 5 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,571 Underlying: Performance Share Units · 12,571 shares Expires not disclosed F4 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F5 · shares: The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 12,571 shares will be issued. The actual number of shares to be issued could range from a low of 2,515 at minimum performance to a high of 25,142 shares at maximum performance. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F6 · derivative.exercise_date: Vests on August 2, 2024. F6 · derivative.expiration_date: Vests on August 2, 2024. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 22:16 UTC | Medtronic plc MDT · Entity 2888 | GrantStock Option (Right to Buy) · Derivative | 1,085 | $0.00 Strike: $131.26 | $0.00 |
DisclosureSEC source: 0001127602-21-023100 · form4.xml · derivative · entry 4 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,085 Underlying: Ordinary Shares · 1,085 shares Expires 2031-08-02 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 22:16 UTC | Medtronic plc MDT · Entity 2888 | GrantStock Option (Right to Buy) · Derivative | 42,961 | $0.00 Strike: $131.26 | $0.00 |
DisclosureSEC source: 0001127602-21-023100 · form4.xml · derivative · entry 3 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,961 Underlying: Ordinary Shares · 42,961 shares Expires 2031-08-02 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 22:16 UTC | Medtronic plc MDT · Entity 2888 | GrantOrdinary Shares | 5,029 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-023100 · form4.xml · nonDerivative · entry 2 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,915 F2 · kind: The restrictions on the award shall lapse 100% on the third anniversary of the Grant Date. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 22:16 UTC | Medtronic plc MDT · Entity 2888 | Tax withholdingOrdinary Shares | 4,905 | $131.31 | $644,075.55 |
DisclosureSEC source: 0001127602-21-023100 · form4.xml · nonDerivative · entry 1 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,886 F1 · balance_after: This balance increased by 782 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| November 03, 2020 Filed Nov 5, 2020 22:59 UTC | Medtronic plc MDT · Entity 2888 | Tax withholdingOrdinary Shares | 273 | $103.13 | $28,154.49 |
DisclosureSEC source: 0001127602-20-028279 · form4.xml · nonDerivative · entry 1 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,009 F1 · balance_after: This balance increased by 281 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| October 09, 2020 Filed Oct 14, 2020 22:47 UTC | Medtronic plc MDT · Entity 2888 | GrantPerformance Share Units · Derivative | 14,723 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-026953 · form4.xml · derivative · entry 1 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,723 Underlying: Performance Share Units · 14,723 shares Expires not disclosed F1 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F2 · shares: The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 14,723 shares will be issued. The actual number of shares to be issued could range from a low of 2,945 at minimum performance to a high of 29,446 shares at maximum performance. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F3 · derivative.exercise_date: Vests on August 3, 2023. F3 · derivative.expiration_date: Vests on August 3, 2023. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:57 UTC | Medtronic plc MDT · Entity 2888 | GrantStock Option (Right to Buy) · Derivative | 36,524 | $0.00 Strike: $97.33 | $0.00 |
DisclosureSEC source: 0001127602-20-022899 · form4.xml · derivative · entry 4 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,524 Underlying: Ordinary Shares · 36,524 shares Expires 2030-08-03 F2 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:57 UTC | Medtronic plc MDT · Entity 2888 | GrantStock Option (Right to Buy) · Derivative | 1,575 | $0.00 Strike: $97.33 | $0.00 |
DisclosureSEC source: 0001127602-20-022899 · form4.xml · derivative · entry 3 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,575 Underlying: Ordinary Shares · 1,575 shares Expires 2030-08-03 F2 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:57 UTC | Medtronic plc MDT · Entity 2888 | GrantStock Option (Right to Buy) · Derivative | 60,453 | $0.00 Strike: $97.33 | $0.00 |
DisclosureSEC source: 0001127602-20-022899 · form4.xml · derivative · entry 2 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,453 Underlying: Ordinary Shares · 60,453 shares Expires 2030-08-03 F2 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:57 UTC | Medtronic plc MDT · Entity 2888 | GrantOrdinary Shares | 6,576 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-022899 · form4.xml · nonDerivative · entry 1 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,001 F1 · kind: The restrictions on these restricted stock units shall lapse 100% on the third anniversary of the Grant Date. Read SEC document |
| July 31, 2020 Filed Aug 3, 2020 21:43 UTC | Medtronic plc MDT · Entity 2888 | Tax withholdingOrdinary Shares | 4,482 | $96.48 | $432,423.36 |
DisclosureSEC source: 0001127602-20-022592 · form4.xml · nonDerivative · entry 1 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,425 F1 · balance_after: This balance increased by 894 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| December 24, 2019 Filed Dec 26, 2019 22:36 UTC | Medtronic plc MDT · Entity 2888 | Exercise / conversionStock Option (Right to Buy) · Derivative | 38,558 | $0.00 Strike: $55.32 | $0.00 |
DisclosureSEC source: 0001127602-19-035863 · form4.xml · derivative · entry 11 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 38,558 shares Expires 2023-07-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option to purchase 38,558 New Medtronic ordinary shares for $55.32 per share, which was partially vested at the effective time of the Merger, was received in the Merger and represents the conversion of 38,558 Medtronic common stock shares for $55.32 per share. This New Medtronic stock option has the same terms and conditions as the original Medtronic stock option. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.